Login to Your Account

Palifosfamide Phase III Blowup

At 'Threshold,' Ziopharm's Bid in Sarcoma Fails; Refocus Due

By Randy Osborne
Staff Writer

Wednesday, March 27, 2013
Ziopharm Oncology Inc.'s Phase III trial with the alkylating agent palifosfamide for first-line, metastatic soft tissue sarcoma failed to meet the primary endpoint of progression-free survival (PFS), but the company – shifting its efforts to synthetic biology programs partnered with Intrexon Corp. – will continue to follow patients' overall survival (OS) rates.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription